Results 111 to 120 of about 18,044 (238)

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Biosimilars [PDF]

Zeitschrift für Rheumatologie, 2013
M. Aringer, T. Dörner
  +5 more sources

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China

Frontiers in Public Health
BackgroundAs China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern.
Xin Du, Xingxian Luo, Qixiang Guo, Qixiang Guo, Xiaomeng Jiang, Xiaomeng Jiang, Ziling Su, Weiting Zhou, Zhongjian Wang, Jiarun Li, Yue Yang, Yue Yang, Yi Zhang   +12 more
doaj   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

What role for real-world evidence in market access of biosimilars?

Frontiers in Pharmacology
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens, Catherine M. Lockhart, Delphine F. Courmier   +2 more
doaj   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia

Фармакоэкономика
Background. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers.
A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova   +5 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars

Biosensors
The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo, Edoardo Marrani, Carmen Gallo, Fosca Errante, Valerio Maniscalco, Anna Maria Papini, Gabriele Simonini, Paolo Rovero, Feliciana Real Fernandez   +8 more
doaj   +1 more source

Review of medicine registration system in Tanzania [PDF]

, 2019
Philosophiae Doctor - PhDRegistration of medicines is an essential function of the national medicine regulatory system of any country. Since the start of the medicine registration system in Tanzania in early 2000s, no systematic review has been carried
KISOMA, SUNDAY
core